Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2014

View Archived Issues

New cost-effective, easy-to-perform, point-of-care tests for the diagnosis of malaria

Takeda presents phase III results for TAK-438

NeoStem signs licensing agreement with Cellular Biomedicine for DC-TC

Otsuka Pharmaceutical profiles pipeline progress of fourth quarter of fiscal 2013

Gene transfer trial for spinal muscular atrophy type 1 begins patient recruitment

AstraZeneca to collaborate with UK Medical Research Council's Laboratory of Molecular Biology

Lipocine reports phase I data for pre-term birth product candidate LPCN-1107

Hemispherx Biopharma enters collaboration to test Alferon N Injection in Tamiflu-resistant strains

Adalimumab receives FDA orphan drug status for uveitis

MK-2206/ridaforolimus combination active in advanced breast cancer

NCL-1 impairs prostate cancer growth in vivo

Tetra Discovery Partners patents new PDE4 inhibitors

Merck & Co. synthesizes novel sodium channel blockers

Selinexor receives orphan drug designation for acute myeloid leukemia

HHS presents adoptive cell transfer-based cancer immunotherapy

Afamelanotide gains FDA and EMA orphan status for benign familial pemphigus

FDA confirms no association between Fluzone and febrile seizures

FDA grants breakthrough therapy designation to elotuzumab

Shire to submit an NDA to the FDA for lifitegrast

Ventrus Biosciences and Assembly Pharmaceuticals in merger agreement

Clovis Oncology's CO-1686 awarded breakthrough therapy designation

Hanmi initiates phase I trial of dual glucagon and GLP-1 receptor agonist

European conditional MAAs withdrawn for vintafolide and companion imaging agents

AstraZeneca rejects Pfizer's final proposal

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.